全国服务咨询热线：
13761418683
13761418683
产品分类
Product Category详细介绍
| 品牌 | absin | CAS | 107097-80-3 |
|---|---|---|---|
| 分子式 | C21H30Cl2N2O5 | 纯度 | 98% |
| 分子量 | 461.38 | 货号 | abs817481 |
| 规格 | 2mg;5mg;10mg;50mg | 供货周期 | 现货 |
| 主要用途 | is CCK receptor antagonist | 应用领域 | 化工,生物产业,农林牧渔,制药/生物制药,综合 |
Loxiglumide 107097-80-3
| 产品描述 | |
| 描述 | Loxiglumide is CCK receptor antagonist. Cholecystokinin receptors or CCK receptors are a group of G-protein coupled receptors which bind the peptide hormones cholecystokinin (CCK) or gastrin. |
| 纯度 | 98% |
| 储存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 别名 | 氯谷胺；CR-1505 |
| 外观 | white to beige powder |
| 可溶性/溶解性 | DMSO : ≥ 100 mg/mL (216.74 mM) |
| 生物活性 | |
| 靶点 | Cholecystokinin Receptor |
| In vivo(体内研究) | The effects of pancreatic rest by oral administration of CCK-1 receptor antagonist Loxiglumide and pancreas stimulation are investigated via endogenous CCK release induced by po protease inhibitor camostat on the recovery of pancreatic secretory function, and biochemical and histological changes of the pancreas after acute hemorrhagic pancreatitis. Oral administration of CCK-1 receptor antagonist Loxiglumide with a dose of 50 mg/kg body weight inhibits pancreatic exocrine secretion for more than 12 h. Thus, every 12-h administration of Loxiglumide might have completely blocks the effect of endogenously released CCK on the pancreas (pancreatic rest). |
| 研究领域 | |
| 研究领域 | MetabolismTypes of diseaseCancer MetabolismTypes of diseaseNeurodegenerative disease MetabolismTypes of diseaseObesity NeuroscienceNeurology processMetabolism NeuroscienceNeurology processNeurodegenerative diseaseAlzheimer's diseaseOther NeuroscienceNeurology processNeurodegenerative diseaseParkinson's diseaseOther Drug DiscoverySmall Molecule DrugLead Compound Discovery |
产品咨询
地址：上海市浦东新区新浩路58号申江科创园18栋
邮箱：zhouzz@univ-bio.com
传真：